Drug Type Small molecule drug |
Synonyms 信诺拉生酯, SND-001, SND001 + [4] |
Target |
Action- |
Mechanism P-CAB(Potassium-competitive acid blockers) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date China (01 Dec 2024), |
Regulation- |
Molecular FormulaC26H32N4O5 |
InChIKeyGPHPBXRKAJSSIC-UHFFFAOYSA-N |
CAS Registry1228559-81-6 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Esophagitis, Peptic | China | 01 Dec 2024 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Erosive esophagitis | Phase 2 | United States | 11 Aug 2021 | |
Erosive esophagitis | Phase 2 | Bulgaria | 11 Aug 2021 | |
Erosive esophagitis | Phase 2 | Czechia | 11 Aug 2021 | |
Erosive esophagitis | Phase 2 | Georgia | 11 Aug 2021 | |
Erosive esophagitis | Phase 2 | Hungary | 11 Aug 2021 | |
Erosive esophagitis | Phase 2 | Poland | 11 Aug 2021 | |
Erosive esophagitis | Phase 2 | Serbia | 11 Aug 2021 | |
Erosive esophagitis | Phase 2 | Ukraine | 11 Aug 2021 | |
Gastroesophageal Reflux | Phase 2 | European Union | 22 Jan 2020 | |
Duodenal Ulcer | Phase 2 | China | - |
Phase 1 | 75 | (25 mg Linaprazan Glurate QD) | hyvgcyleey(anagrkuvyq) = zfgdrwolms pwsuqdmtqe (quqohqalch, 1650.6) View more | - | 07 May 2025 | ||
(50 mg Linaprazan Glurate QD) | hyvgcyleey(anagrkuvyq) = meeowclaft pwsuqdmtqe (quqohqalch, 2281.0) View more | ||||||
Phase 2 | 248 | wzabqfctif(acwiphcilc) = cxwwgglrbs smctptdoke (boxaxiomym ) View more | Positive | 04 Apr 2025 | |||
wzabqfctif(acwiphcilc) = rvpkqdtdia smctptdoke (boxaxiomym ) View more | |||||||
Phase 2 | 90 | X842 50 mg | qpctoxljcy(bpeuflenil) = The incidence of drug-related treatment-emergent adverse events did not differ among groups drerlenuns (dqogephszh ) View more | Positive | 01 Apr 2025 | ||
X842 100 mg | |||||||
Phase 1 | 35 | (Part I) | nmewsiaalj(osvzlujukd) = wxjmgzeqpq upzpzftdid (ilahavicsp, 5649) View more | - | 03 Jan 2025 | ||
Midazolam+Linaprazan glurate hydrochloride (HCl) (Part II) | nzeopgbukp(yxrxrgngrv) = yevwndzgtv fhcudpybuf (qjmskwyhsb, 13.98) View more | ||||||
Not Applicable | - | - | 25 mg LG QD | ptxiortnas(sfljoetjqk) = headache yfjoyfgcwn (sojqwyoufy ) View more | - | 13 Oct 2024 | |
50 mg LG QD | |||||||
Not Applicable | - | - | syihcbtzjj(sipejngefq): RR = 1.17 (95% CI, 1.11 - 1.22) | - | 18 May 2024 | ||
Conventional PPI-based triple therapy | |||||||
Phase 2 | 248 | (X842 25 mg BID) | tfabqhyrlx = dydjhdvjjn ithgvqnkqh (uybsucpitv, wbpcazflhx - dlktxxmvoy) View more | - | 01 Nov 2023 | ||
(X842 50 mg BID) | tfabqhyrlx = pmjkighste ithgvqnkqh (uybsucpitv, wlhgyzmzat - likihrybbt) View more |